The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
TwelvesC., CortesJ., VahdatL.Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. Clin Breast Cancer.2010; 10(2): 160–163.
2.
VahdatL., PruittB., FabianC.Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol.2009; 27(18): 2954–2961.
3.
CortesJ., VahdatL., BlumJ.Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously with an anthracycline, a taxane, and capecitabine. J Clin Oncol.2010; 28(25): 3922–3928.
4.
Halaven [package insert].Woodcliff Lake, NJ: Eisai, Inc; 2010.
5.
TanA., RubinE., WaltonD.Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors. Clin Cancer Res.2009; 15(12): 4213–4219.
FazaziK., LiptonA., MarietteX.Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol.2009; 27(10): 1564–1571.
12.
LiptonA., StegerG., FigueroaJ.Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related metasases. J Clin Oncol.2007; 25(28): 4431–4437.
13.
LiptonA., StegerG., FigueroaJ.Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clin Cancer Res.2008; 14(20): 6690–6696.
14.
SmithM., EgerdieB., TorizN.Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med.2009; 361(8): 745–755.
CummingsS., San MartinJ., McClungM.Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med.2009; 361(8): 756–765.
